FPH - Fisher & Paykel Healthcare profile
This is a basic profile of an NZX50 listed company. It is not investment advice. We recommend you contact a qualified adviser if you need more information.
Fisher & Paykel Healthcare
Directory
| NZX code: | FPH |
| Short name: | Fisher & Paykel |
| Legal name: | Fisher & Paykel Healthcare Corporation Limited |
| Industry sector: | Healthcare equpiment |
| NZX50 rank: | 1 of 50 |
| Head office address: | 15 Maurice Paykel Place, Auckland, 1061 |
| Chairman: | Scott St John |
| Chief executive: | Lewis Gradon |
| Financial year ended: | March |
| Locations: | New Zealand, Australia, Mexico |
| Auditor: | Pwc |
| Bankers: | [not revealed] |
Financial statement history
A. Recent trading and performance summary:
| Total revenue |
NPAT | Dividend per share |
|
| fye March | bln | mln | cents |
| 2017 | $0.894 | $169 | 19.5 |
| 2018 | $0.981 | $190 | 21.25 |
| 2019 | $1.070 | $209 | 23.25 |
| 2020 | $1.264 | $287 | 27.50 |
| 2021 | $1.971 | $524 | 38.00 |
B. Recent financial position summary:
| Total assets |
Total Liabilities |
Equity ratio |
|
| fye March | bln | mln | % |
| 2017 | $0.88 | $217 | 75.3 |
| 2018 | $1.03 | $264 | 74.4 |
| 2019 | $1.21 | $294 | 75.7 |
| 2020 | $1.44 | $461 | 68.0 |
| 2021 | $2.08 | $554 | 73.4 |
C. Recent cash flows and positions:
| Cash inflows |
Cash outflows |
Cash and equiv. at year end |
|
| fye March | mln | mln | mln |
| 2017 | $193.6 | $150.7 | $45.6 |
| 2018 | $247.8 | $277.6 | $15.8 |
| 2019 | $253.3 | $238.8 | $30.9 |
| 2020 | $321.4 | $314.7 | $36.4 |
| 2021 | $625.3 | $575.3 | $85.4 |
Description of trading activities
Fisher & Paykel Healthcare is a manufacturer, designer and marketer of products and systems for use in respiratry care, acute care, and the treatment of obstructive sleep apnea. Fisher & Paykel Healthcare has a purpose of improving care and outcomes through inspired, world-leading healthcare solutions.
CEO profile
Lewis became Managing Director & Chief Executive Officer in April 2016. Prior to that, he spent 15 years as Senior Vice President – Products & Technology, and six years as General Manager – Research and Development. During his 37-year tenure with Fisher & Paykel Healthcare he has held various engineering positions overseeing the development of our range of products as well the development of our manufacturing, quality, intellectual property, supply chain and clinical research functions. He has a Bachelor of Science – Physics
Chairman profile
Scott is Chancellor of the University of Auckland and a director of Mercury Limited, the NEXT Foundation and Fonterra Cooperative Group Limited. Scott was Chief Executive Officer of First NZ Capital from 2002 to 2017. He is a member of Chartered Accountants Australia and New Zealand and a fellow of the Institute of Finance Professionals of New Zealand. He has Bachelor of Commerce, Diploma in Business
Links:
| Company website: | https://www.fphcare.com/nz/ |
| Investor information: | https://www.fphcare.com/nz/our-company/investor/ |
| NZX listing: | https://www.nzx.com/companies/FPH |
| Annual reports: | https://www.fphcare.com/nz/our-company/investor/ |